Issues

Home > Issues (Page 16)

April 14, 2021 Issues, Policy Proposals

Policymakers across the globe are attempting to vilify the same private companies that have been invaluable partners in the fight against the COVID-19 pandemic. If these efforts are successful, it will be patients who are harmed the most. Globally, the World Trade Organization (WTO) wants to waive the patent rights for the companies that developed effective COVID-19 vaccines in record breaking time. Here in the U.S., states as diverse as Arkansas, California, and Texas are considering policies that use the pandemic as an...

April 12, 2021 Policy Proposals

For more than a century, National Geographic has produced a high-quality magazine that is well-grounded in science, history and culture. Lately, however, the editors have allowed agenda-driven articles based on flawed research to slip in between the covers. Take, for example, the latest piece by science writer Elizabeth Royte, which focused on the work of Jonathan Lundgren, who is portrayed as a hard-working scientist-farmer. He claims that widely used, state-of-the-art neonicotinoid insecticides “may be a threat to mammals,” as well as to...

April 9, 2021 Industry Trends

As Congress once again takes up legislation to reduce drug prices, one of the most important yet overlooked areas for reform is rebate walls. Rebate walls, also known as rebate traps, block competition in parts of the U.S. prescription drug market, especially immunology, which is home to some of the costliest drugs. They can favor older, more expensive and even less effective drugs over newer, more effective, and often cheaper alternatives. Thanks to rebate walls, patients are routinely forced to “fail first”...

April 8, 2021 CoronaVirusSlide3

I've been a science nerd almost all my life. In graduate school, I was the co-discoverer of a bacterial enzyme essential to DNA replication and of a key enzyme in the influenza virus. I have written more than a thousand articles concerned with science and science policy. I'm convinced that America's prosperity is based on post-WWII preeminence in science and technology, much of it financed by federal funding. You might think, then, that I'd be thrilled to learn that the science committee of the U.S. House of...

April 7, 2021 Coronavirus - Alternate

Henry Miller, M.S., M.D. and Lars Larson talk about vaccine "passports" and the concern that documentation for vaccines could be expanded for other uses. Larson compares the vaccine passports to the widespread use of social security cards and the pending policy questions from requiring medical documentation. Lars Larson National Podcast · Lars Larson National Podcast 04-06-21...

April 7, 2021 Coronavirus

Dr. Rochelle Walensky, the director of the Centers for Disease Control and Prevention, recently expressed a sense of "impending doom" regarding the pandemic. Her fear is that, unless Americans keep abiding by strict Covid-19 protocols like mask-wearing, social distancing, and forgoing travel, a new surge in cases and deaths could be on the horizon. "I so badly want to be done," Walensky said. "So I'm asking you to just hold on a little longer." Dr. Scott Gottlieb, the former commissioner of the Food and...

April 1, 2021 Coronavirus-Alternate2

Dr. Henry Miller, M.S., M.D. joins the Lars Larson Show to discuss the impact of pesticides, GMOs, and agricultural chemicals and the role these products play in crop production. Miller talks about the umbrella term of pesticides, herbicides (removal of invasive plants), and insecticides (removal of harmful insects), and the impact of the environmental movement on how these products and practices are viewed. Lars Larson National Podcast · Lars Larson National Podcast 03-30-21...

March 31, 2021 Blog, Policy Proposals, Value

Despite the constant stream of dour news about drug prices, actions by employer-sponsored plans are providing reasons for hope. Instead of accepting the high-cost of originator biologics, companies as diverse as Disney, Costco, and CalPERS are “asserting their own desire to see biosimilars implemented among their employees.” Capturing these savings during the pandemic only increases their importance. Biologic medicines are high valued drugs that have meaningfully improved patient health, particularly for people living with cancer and auto-immune diseases. These medicines are also...

March 29, 2021 Coronavirus - Alternate

Anyone active on social media is aware that there is a great deal of passionate but ill-founded opposition to vaccination, including to the new COVID-19 vaccines. How could that be? Physicians and the public health establishment are constantly promoting vaccination, especially as we try to stem the tide of the coronavirus pandemic. It turns out that the anti-vaccine sentiment is the product of what can only be described as an industry whose principal protagonists are an organized group of professional propagandists. As recently reported in the...

March 24, 2021 Policy Proposals

By Robert Popovian and Wayne Winegarden The time has come for us to think about incremental, evolutionary, and targeted changes to the healthcare system to reduce costs rather than focusing on grand bargains. It is time for practical solutions that will likely have broad consensus amongst patients, providers, employers, and policymakers. While the debate over the merits of private sector healthcare solutions versus government control of healthcare continues, a group of policy experts with support from the Arnold Ventures and Tobin Center...

March 22, 2021 Coronavirus

President Joe Biden recently toured a Pfizer plant in Kalamazoo, Mich., where workers are churning out millions of lifesaving COVID-19 vaccine doses. During his remarks, he mentioned that in mid-February he had “toured the Vaccine Research Center at the National Institutes of Health . . . [where] I met world-class doctors, scientists, and researchers who were critical for discovering the vaccines in record time.” Frankly, the president is giving the government too much credit. While federal grants and purchase agreements certainly helped...

March 17, 2021 Briefs, Price and Costs, Studies

A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no reason to believe that these estimates accurately reflect the value of medicines,” said Dr. Wayne Winegarden, the brief’s author.  “The documented biases in their value assessments should raise serious concerns that...

March 15, 2021 Coronavirus-Alternate2

Andrew I. Fillat and Henry I. Miller "Science, at its core, is a social phenomenon." This observation, from Alondra Nelson, the newly appointed deputy director of President Biden's Office of Science and Technology Policy (OSTP), certainly qualifies for a prominent place in the Pantheon of Inane Statements. The core of science, in fact, is the scientific method—posing and testing hypotheses; carefully gathering, examining, and generating experimental evidence; and finally, synthesizing all the available information into logical conclusions. Dr. Nelson's assertion is inauspicious, but perhaps...

March 10, 2021 Coronavirus

Dr. Henry Miller, PRI's senior fellow, joins the nationally-syndicated Lars Larson Show to talk about the difference in COVID-19 vaccine efficacy or intended result between the Pfizer, Moderna, and Johnson & Johnson vaccines, with the vaccines ranging from 60 to 90 percent. Miller explains that there is more context to the vaccine efficacy explanation, which depends on when they were tested, approved for emergency use, and available testing at the time of the clinical trials. Miller also talks about the roles...

March 4, 2021 Coronavirus - Alternate

During the past year, many thousands of articles and commentaries have been published on almost every imaginable aspect of the SARS-Cov-2 virus and the COVID-19 pandemic it has caused. They have appeared online, in journals, on preprint servers, in newspapers, and on Facebook and Twitter, to say nothing of local electronic bulletin boards. TV news programs continue to feature prominently the latest developments and statistics. As the rollout of COVID-19 vaccines has progressed throughout the country, a prominent issue is vaccine hesitancy –...

March 4, 2021 Coronavirus

By Henry Miller, M.S., M.D. and John Cohrssen Over the weekend, the FDA issued an emergency-use authorization for Johnson & Johnson's Covid-19 vaccine, clearing the path to market for the third coronavirus vaccine. The FDA had previously approved the Pfizer-BioNTech and Moderna Covid vaccines in record time—mere weeks after their makers submitted results of the clinical studies demonstrating safety and efficacy. When the FDA wants to, it can get desperately needed products expeditiously to those who need them. But for some other...

March 4, 2021 Coronavirus

Dr. Henry Miller joins the Dan Proft Show to discuss the latest re-openings of states like Texas and how they may pose challenges to stopping the spread of COVID-19. Miller and Proft discuss the different lockdown measures in other states and how that impacts lockdown policies throughout the United States. ...

March 4, 2021 Coronavirus-Alternate2

A just-announced policy change from the newly reinvigorated CDC specifies that persons who may have been exposed to COVID-19 no longer need to quarantine if they've been fully vaccinated within the previous 90 days. (People who aren't vaccinated are still supposed to quarantine for 14 days after they have been in close contact with someone who has COVID-19.) The new policy states: At this time, vaccinated persons should continue to follow current guidance to protect themselves and others, including wearing a mask, staying at least 6 feet away...

March 4, 2021 Blog, Industry Trends

Patent trolls have been a plague on innovators for too long. Patent trolls are entities that obtain patents (sometimes obscure patents) for the sole purpose of threatening or filing lawsuits in court and then using the prospect of costly litigation to extort unwarranted payouts from an innovative company. The risks and costs created by these entities are a clear and present danger to entrepreneurship and innovation. A goal of public policy should be to make it more costly for frivolous patent...